Combined prognostic value of lipoprotein(a) and an integrated inflammatory-lipid index in patients with acute coronary syndrome and type 2 diabetes mellitus - Scorecard - MDSpire
Advertisement
Combined prognostic value of lipoprotein(a) and an integrated inflammatory-lipid index in patients with acute coronary syndrome and type 2 diabetes mellitus
Clinical Scorecard: Prognostic Significance of Lipoprotein(a) and a Novel Inflammatory-Lipid Index in Individuals with Acute Coronary Syndrome and Type 2 Diabetes Mellitus
At a Glance
Category
Detail
Condition
Key Mechanisms
Lipoprotein(a) [Lp(a)] and Inflammatory-Lipid Index (hs−CRP × (ApoB/ApoA1)) as independent predictors of major adverse cardiovascular events (MACE) based on study findings.
Target Population
Care Setting
Key Highlights
Study analyzed 1,910 patients over a median follow-up of 5.5 years.
Dual-high group (high Lp(a) and high Inflammatory-Lipid Index) had a MACE incidence of 57.7%.
Addition of Lp(a) and Inflammatory-Lipid Index improved predictive performance (C-statistic: 0.741).
Both biomarkers are independent predictors of MACE as per study results.
The study introduces a novel Inflammatory-Lipid Index for risk stratification.
Guideline-Based Recommendations
Diagnosis
Assess Lp(a), hs-CRP, and ApoB/ApoA1 in patients with ACS and T2DM as per study findings.
Management
Consider dual-biomarker approach for cardiovascular risk stratification based on study results.
Monitoring & Follow-up
Regularly evaluate Lp(a) and Inflammatory-Lipid Index in high-risk patients as indicated by study.
Risks
Patients with dual-high markers face an 8-fold higher risk of MACE according to study data.
Patient & Prescribing Data
Conventional lipid profiles may not capture complete atherogenic risk; consider non-traditional biomarkers as suggested by study.
Clinical Best Practices
Integrate Lp(a) and Inflammatory-Lipid Index for comprehensive risk assessment as per study findings.
Utilize multivariable Cox regression for predictive analysis as indicated in the study.
